Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Apr 15, 2024; 16(4): 1166-1179
Published online Apr 15, 2024. doi: 10.4251/wjgo.v16.i4.1166
Published online Apr 15, 2024. doi: 10.4251/wjgo.v16.i4.1166
Figure 6 Metastatic treatments recommendations.
NET: Neuroendocrine tumours; NEC: Poorly differentiated neuroendocrine cancers; Non-NE: Non-neuroendocrine; M: Month; 1L: First line treatment; 2L: Second line treatment; FOLFIRI: Irinotecan plus 5-fluorouracil; CAPTEM: Capecitabine plus temozolamide; BV: Bevacizumab; STZ: Streptozocin; MMR: Mismatch repair; SSTR-5: Expression of somatostatin receptor type 5; PRRT: Radiotherapy with radionuclides; AS: Somatostatin anologues; FOLFOX: Oxaliplatin plus 5-fluorouracil.
- Citation: Díaz-López S, Jiménez-Castro J, Robles-Barraza CE, Ayala-de Miguel C, Chaves-Conde M. Mixed neuroendocrine non-neuroendocrine neoplasms in gastroenteropancreatic tract. World J Gastrointest Oncol 2024; 16(4): 1166-1179
- URL: https://www.wjgnet.com/1948-5204/full/v16/i4/1166.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i4.1166